Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends GNCA vs. SCPS, VAXX, EVLO, CMRA, ARDS, CALA, AMPE, CLVR, EFTR, and PXMDShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), eFFECTOR Therapeutics (EFTR), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Calithera Biosciences Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics PaxMedica Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Does the MarketBeat Community prefer SCPS or GNCA? Genocea Biosciences received 386 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 56.40% of users gave Genocea Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesGenocea BiosciencesOutperform Votes38856.40% Underperform Votes30043.60% Do institutionals and insiders hold more shares of SCPS or GNCA? 0.6% of Genocea Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is SCPS or GNCA more profitable? Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Genocea Biosciences N/A -182.88%-62.76% Which has preferable earnings & valuation, SCPS or GNCA? Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/A Does the media prefer SCPS or GNCA? In the previous week, Genocea Biosciences had 1 more articles in the media than Scopus BioPharma. MarketBeat recorded 1 mentions for Genocea Biosciences and 0 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Genocea Biosciences Neutral Which has more volatility and risk, SCPS or GNCA? Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. SummaryScopus BioPharma and Genocea Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6,000.00$3.11B$5.84B$9.14BDividend YieldN/A1.55%4.75%3.86%P/E Ratio0.0030.1126.7919.19Price / SalesN/A329.47435.4570.88Price / CashN/A168.8738.0134.83Price / BookN/A3.687.644.62Net Income-$33.20M-$71.72M$3.19B$246.06M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastSCPSScopus BioPharmaN/A$0.00flatN/A-91.7%$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-95.3%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.4%$6,000.00$630,000.000.002High Trading VolumeARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5,000.00$3.09M0.0030Gap UpHigh Trading VolumeCALACalithera BiosciencesN/A$0.00flatN/A-97.0%$3,000.00N/A0.0060Analyst ForecastNews CoverageAMPEAmpio PharmaceuticalsN/A$0.00-79.0%N/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoverageGap DownHigh Trading VolumeCLVRClever LeavesN/A$0.00-50.0%N/A-100.0%$2,000.00$17.42M0.00560Gap DownHigh Trading VolumeEFTReFFECTOR Therapeutics1.0612 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010PXMDPaxMedicaN/A$0.00-99.7%N/A-100.0%$1,000.00N/A0.002Gap Down Related Companies and Tools Related Companies SCPS Competitors VAXX Competitors EVLO Competitors CMRA Competitors ARDS Competitors CALA Competitors AMPE Competitors CLVR Competitors EFTR Competitors PXMD Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNCA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
